The National Institutes of Health (NIH) has partnered with several biopharmaceutical companies and nonprofits in a bid to speed the development of new drugs and diagnostics.
New technologies, including advanced imaging and genomics, have identified thousands of disease-associated genes, proteins, and other molecules, according to the NIH. But few have been converted into potential treatments or diagnostics, in part because the process is long and fraught with failure. The NIH estimates that it takes a decade and $1 billion to turn a biological candidate into a product approved by the Food and Drug Administration (FDA), and 95% of the candidates fail somewhere along the way.
Kuehn BM. Public-Private Groups Seek Drug Targets. JAMA. 2014;311(12):1192. doi:10.1001/jama.2014.3085